These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

89 related articles for article (PubMed ID: 21089710)

  • 1. [Research and development strategy of agents for the treatment of metabolic diseases].
    Matsuo T; Yukioka H
    Nihon Yakurigaku Zasshi; 2010 Nov; 136(5):255-8. PubMed ID: 21089710
    [No Abstract]   [Full Text] [Related]  

  • 2. Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.
    Sacks FM
    Am J Cardiol; 2008 Dec; 102(12A):1L-3L. PubMed ID: 19084082
    [No Abstract]   [Full Text] [Related]  

  • 3. Protective role of pravastatin in the pathogenesis of the metabolic syndrome.
    Yamagishi S; Matsui T; Sato T; Takeuchi M
    Med Hypotheses; 2006; 66(3):609-11. PubMed ID: 16171951
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Early pharmacological intervention in newly diagnosed metabolic syndrome and type 2 diabetes.
    Naruszewicz M
    Przegl Lek; 2006; 63 Suppl 4():7-8. PubMed ID: 16967707
    [No Abstract]   [Full Text] [Related]  

  • 5. Metabolic Diseases Drug Discovery World Summit--SRI conference. Diabetes and obesity. 28-29 July 2003 San Diego, CA, USA.
    Xu J
    IDrugs; 2003 Sep; 6(9):850-1. PubMed ID: 14565170
    [No Abstract]   [Full Text] [Related]  

  • 6. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [A comment to the Klaringsrapport nr 6, 2000 "Type 2 diabetes and the metabolic syndrome--diagnosis and treatment"].
    Hallager K
    Ugeskr Laeger; 2000 Sep; 162(36):4824. PubMed ID: 10994385
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
    Grundy SM
    Nat Rev Drug Discov; 2006 Apr; 5(4):295-309. PubMed ID: 16582875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is liver disease a threat to patients with metabolic disorders?
    Marchesini G; Forlani G; Bugianesi E
    Ann Med; 2005; 37(5):333-46. PubMed ID: 16179269
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and treatment of metabolic syndrome in adolescents with type 2 diabetes.
    Sanders BH; Lubsch LM; West DS
    Ann Pharmacother; 2006 Sep; 40(9):1517-21. PubMed ID: 16896016
    [TBL] [Abstract][Full Text] [Related]  

  • 11. AMPK: an emerging drug target for diabetes and the metabolic syndrome.
    Zhang BB; Zhou G; Li C
    Cell Metab; 2009 May; 9(5):407-16. PubMed ID: 19416711
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Herbals used for diabetes, obesity, and metabolic syndrome.
    Najm W; Lie D
    Prim Care; 2010 Jun; 37(2):237-54. PubMed ID: 20493334
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.
    Steiner G
    Am J Cardiol; 2008 Dec; 102(12A):28L-33L. PubMed ID: 19084087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting farnesoid X receptor for liver and metabolic disorders.
    Fiorucci S; Rizzo G; Donini A; Distrutti E; Santucci L
    Trends Mol Med; 2007 Jul; 13(7):298-309. PubMed ID: 17588816
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fibrates in the metabolic syndrome and in diabetes.
    Steiner G
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):545-55, vi-vii. PubMed ID: 15262296
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes.
    Di Marzo V; Piscitelli F; Mechoulam R
    Handb Exp Pharmacol; 2011; (203):75-104. PubMed ID: 21484568
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Therapeutic potential of alpha-glucosidase-inhibitors.
    Fölsch UR
    Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
    [No Abstract]   [Full Text] [Related]  

  • 18. Combination therapy for obesity and metabolic disease.
    Gadde KM; Allison DB
    Curr Opin Endocrinol Diabetes Obes; 2009 Oct; 16(5):353-8. PubMed ID: 19625958
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
    Haffner SM; Ruilope L; Dahlöf B; Abadie E; Kupfer S; Zannad F
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mechanisms of disease: Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 as a novel treatment for the metabolic syndrome.
    Tomlinson JW; Stewart PM
    Nat Clin Pract Endocrinol Metab; 2005 Dec; 1(2):92-9. PubMed ID: 16929377
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.